Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mercy Research | OTHER |
Not provided
Not provided
Not provided
Pregnant women are a vulnerable and high-risk population, as COVID-19 is associated with an increased risk preterm birth, cesarean section, and maternal critical care. This study will examine the factors that impede testing for SARS-CoV-2 (the causative virus among pregnant women), help determine optimal testing strategies by evaluating the necessity of testing for asymptomatic disease in pregnancy, inform prenatal care plans by assessing the full impact of infection, and contribute to a provider's ability to counsel women and create prenatal care plans if they are pregnant or considering pregnancy.
Pregnant women are a vulnerable and high-risk population, as COVID-19 is associated with an increased risk of preterm birth, cesarean section, and maternal intensive care. The objectives of this study are to: (a) evaluate the full impact of SARS-CoV-2 in pregnancy to inform testing strategies, (b) examine the factors that impede testing during pregnancy, and (c) use study data to devise implementation strategies that improve SARS-CoV-2 testing in pregnancy and prenatal care during the pandemic. Investigators will prospectively enroll two cohorts of pregnant women: 1) exposed (SARS-CoV-2 positive), and 2) unexposed (SARS-CoV-2 negative as defined by antibody testing at the beginning of pregnancy, every trimester, and at delivery). Women who initially enroll as unexposed but later test positive for SARS-CoV-2 antibodies will cross over to the exposed cohort. In Aim 1, investigators will evaluate patients' and providers' perceptions of SARS-CoV-2 testing during pregnancy and the influence of COVID-19 on maternal care-seeking behavior and anxiety via surveys and semi-structured interviews. In Aim 2, investigators will determine the effect of SARS-CoV-2 infection during pregnancy on the risk of preterm birth and other adverse pregnancy outcomes in symptomatic and asymptomatic disease. It is hypothesized that SARS-CoV-2 infection will increase the risk of preterm birth by 12%. In Aim 3, investigators will estimate the risk of mother-to-fetus SARS-CoV-2 transmission and viral presence in umbilical cord blood, placenta, and amniotic fluid by assaying for viral RNA in the neonate, cord blood, and placenta. Collectively, Aims 1-3 will be interpreted by investigators, the Scientific Advisory Board and the Community Advisory Board who will apply data to devising targeted implementation strategies designed for rapid community dissemination to improve testing and prenatal care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Unexposed (SARS-CoV-2 negative) cohort | Placebo Comparator | Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy. |
|
| Exposed (SARS-CoV-2 positive) cohort | Active Comparator | Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antibody testing for SARS-CoV-2 IgG | Diagnostic Test | Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization. |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of preterm delivery | Childbirth prior to 37 weeks of pregnancy, to be determined in accordance to standard pregnancy dating and the established estimated due date. | 20 weeks gestation until childbirth |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of preeclampsia | Standard definitions will be used (new-onset presence of elevated blood pressure > 140 systolic or > 90 diastolic separated by >4 hours and new onset proteinuria after 20 weeks of pregnancy or evidence of severe features of preeclampsia). | After 20 weeks gestation and up to 6 weeks postpartum |
Not provided
Inclusion Criteria for exposed (SARS-CoV-2 positive) cohort:
Exclusion Criteria for exposed (SARS-CoV-2 positive) cohort:
Inclusion Criteria for unexposed (SARS-CoV-2 negative) cohort:
Exclusion Criteria for unexposed (SARS-CoV-2 negative) cohort:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Megan E Foeller, MD | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University Medical Center | St Louis | Missouri | 63110 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective study that will enroll two cohorts of pregnant women: 1) exposed (SARS-CoV-2 positive), and 2) unexposed (SARS-CoV-2 negative as defined by antibody testing at the beginning of pregnancy, every trimester, and at delivery). Women who initially enroll as unexposed but later test positive for SARS-CoV-2 antibodies will cross over to the exposed cohort. Outcomes will be compared between the two cohorts.
Not provided
Not provided
Not provided
Not provided
| Testing for SARS-CoV-2 RNA | Diagnostic Test | Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available. |
|
| Testing for SARS-CoV-2 IgM/IgG | Diagnostic Test | Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available. |
|
| Rate of gestational hypertension |
Standard definitions of gestational hypertension will be used (new-onset presence of elevated blood pressure > 140 systolic or > 90 diastolic separated by >4 hours without proteinuria after 20 weeks of pregnancy). |
| After 20 weeks gestation and up to 6 weeks postpartum |
| Rate of cesarean section | Delivery via a cesarean section operation. | Time of delivery |
| Rate of stillbirth | Fetal demise in utero after 20 weeks gestation. | Between 20 weeks gestation and childbirth |
| Rate of fetal growth restriction | Estimated fetal weight by sonographic assessment less than the 10th percentile for gestational age. | Between conception and childbirth |
| Rate of fetal hydrops | The presence of abnormally located fluid collections in two or more areas in the fetal body (i.e., fetal ascites and pericardial effusion) or one abnormal fluid collection plus fetal skin thickening. | Between conception and childbirth |
| Rate of oligohydramnios | Estimated amniotic fluid index less than 5 or estimated deepest vertical pocket (no presence of umbilical cord) less than 2 by sonographic assessment. | Between conception and childbirth |
| Perinatal death | Fetal or neonatal death occurring after 20 weeks gestation and up to 21 days of life. | During the pregnancy after 20 weeks of pregnancy to 21 days after delivery |
| Rate of premature preterm rupture of membranes | Rupture of membranes prior to 37 weeks gestation. | Between conception and 36 weeks 6 days of pregnancy |
| Rate of neonatal intensive care unit (NICU) admission | Admission of the newborn to the NICU after delivery during delivery hospitalization. | After delivery of newborn during delivery hospitalization |
| Rate of neonatal sepsis | Clinical syndrome that includes systemic signs of infection and bacteremia. | After delivery of newborn during delivery hospitalization up to 6 weeks of life |
| Rate of oxygen therapy | Use of oxygen therapy for the newborn after delivery during delivery hospitalization. | After delivery of newborn during delivery hospitalization up to 6 weeks of life |
| Percentage of infants with low 5-minute Apgar | Five minute Apgar less than 7. Maximum 10, minimum 0. Higher scores typically have improved outcomes. | At time of delivery |
| Percentage of infants with abnormal umbilical cord gas | pH of arterial blood of umbilical cord blood less than 7 and/or base excess greater than -12. | At time of delivery |
| Low birth weight | Weight at birth less than 2,500 grams. | At time of delivery |
| Confirmed congenital infection | SARS-CoV-2 RNA detection in the umbilical cord blood, in amniotic fluid if collected before rupture of membranes or in neonatal nasopharyngeal swabs collected both immediately after birth (and after cleaning of the infant). | Testing will be conducted at time of delivery. |
| Probable congenital infection | SARS-CoV-2 RNA detection in the neonatal nasopharyngeal swabs collected immediately after birth (after cleaning of infant) and in the fetal side of the placenta. | At time of delivery |
| Possible congenital infection | Anti-SARS-CoV-2 IgM antibodies detection in the umbilical cord blood but no SARS-CoV-2 RNA detected in the neonate. | At time of delivery |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D018352 | Coronavirus Infections |
| D047928 | Premature Birth |
| D011248 | Pregnancy Complications |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000917 | Antibody Formation |
| ID | Term |
|---|---|
| D007110 | Immunity, Active |
| D056704 | Adaptive Immunity |
| D007109 | Immunity |
| D055633 | Immune System Phenomena |
Not provided
Not provided